Loading...
Loading...
XAIR| Name | Value |
|---|---|
| Revenues | 0.1M |
| Cost of Revenue | 0.3M |
| Gross Profit | -0.2M |
| Operating Expense | 15.6M |
| Operating I/L | -15.9M |
| Other Income/Expense | 0.8M |
| Interest Income | 0.0M |
| Pretax | -15.1M |
| Income Tax Expense | -0.9M |
| Net Income/Loss | -14.1M |
Beyond Air, Inc. is a commercial medical device and biopharmaceutical company specializing in the development of the LungFit platform, a nitric oxide generator and delivery system. The company's flagship product, LungFit PH, is designed for the treatment of persistent pulmonary hypertension of the newborn. Additionally, Beyond Air is working on LungFit PRO for the treatment of viral lung infections, including COVID-19, and LungFit GO for nontuberculous mycobacteria. The company generates revenue through the sale of its medical devices and biopharmaceutical products, catering to the needs of patients with respiratory conditions and viral lung infections.
